BioCardia, Inc. (BCDA) stock
BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.77−0.02 (-2.06%)
Close on Nov 18, 2026Market cap $11.69MP/E –Yield –
BioCardia free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
BioCardia's free cash flow for the twelve months ending Jun 30, 2026 was -$7.57M. For fiscal 2025 it was -$7.44M. The highest annual figure on record is -$310.00K in fiscal 2012.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.44M | – |
| FY2024 | Dec 31, 2024 | -$7.89M | – |
| FY2023 | Dec 31, 2023 | -$9.99M | – |
| FY2022 | Dec 31, 2022 | -$10.63M | – |
| FY2021 | Dec 31, 2021 | -$10.48M | – |
| FY2020 | Dec 31, 2020 | -$12.39M | – |
| FY2019 | Dec 31, 2019 | -$9.59M | – |
| FY2018 | Dec 31, 2018 | -$11.14M | – |
| FY2017 | Dec 31, 2017 | -$8.81M | – |
| FY2015 | Dec 31, 2015 | -$7.15M | – |
| FY2012 | Dec 31, 2012 | -$310.00K | – |
| FY2011 | Dec 31, 2011 | -$3.22M | – |
| FY2010 | Dec 31, 2010 | -$5.35M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.74M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.66M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.50M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.67M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.65M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.62M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.43M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.61M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.53M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.85M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.41M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.15M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.57M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.00M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.02M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.67M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.94M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.02M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.66M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.89M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.91M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.42M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.63M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.35M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.00M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.26M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.49M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.32M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.52M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.26M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.01M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.82M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.04M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.55M | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.78M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.13M | – |
| Q1 FY2017 | Mar 31, 2017 | -$2.34M | – |
See a number that looks wrong?